1 i) secretion of pre-formed IL-8, and Charcot Leyden crystal (CLC) formation, which was most evident i

2                                      Charcot-Leyden crystal (CLC) protein, initially reported to poss

3                                      Charcot-Leyden crystals (CLCs) are Galectin-10 protein crystals

4 ophic factor in nasal secretions and Charcot-Leyden crystal protein in serum.

5 n 1, EDN, eosinophil peroxidase, and Charcot-Leyden crystal protein/galectin-10 showed significant co

6 l extracellular traps cell death and Charcot-Leyden crystals, but independent of IL-17.

7                 The human eosinophil Charcot-Leyden crystal (CLC) protein is a member of the Galectin

8  eosinophil-rich diseases in humans (Charcot-Leyden crystals).

9                           In humans, Charcot-Leyden crystals (CLCs) are made from galectin-10 (Gal10)

10 s (6-gene signature [6GS], including Charcot-Leyden crystal galectin [CLC]; carboxypeptidase 3 [CPA3]

11 in the accumulation of intracellular Charcot-Leyden-like crystals in alveolar macrophages by wk 4 and

12  age that included the appearance of Charcot-Leyden crystals.

13                      The presence of Charcot-Leyden-like crystals in airway macrophages and the incre

14 s cell metaplasia, the deposition of Charcot-Leyden-like crystals, airway fibrosis, eotaxin productio

15  and acidic mucus, the deposition of Charcot-Leyden-like crystals, and subepithelial airway fibrosis

16                                  The Charcot-Leyden crystal (CLC) protein, or eosinophil lysophosphol

17 thymic stromal lymphopoietin (TSLP), Charcot-Leyden crystal (CLC), C-C motif chemokine receptor 3 (CC

18 ers for emerging electrical treatments: with Leyden jars, with galvanic and electromagnetic machines,